{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T12:52:24Z","timestamp":1780318344816,"version":"3.54.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012470","name":"Doctoral Program Foundation of Institutions of Higher Education of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012470","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007121","name":"Hefei Institutes of Physical Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007121","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003995","name":"Anhui Provincial Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005063","name":"Anhui Province Excellent Young Talents Fund Program of Higher Education Institutions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005063","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.ejphar.2021.173944","type":"journal-article","created":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T20:15:19Z","timestamp":1612988119000},"page":"173944","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML)"],"prefix":"10.1016","volume":"897","author":[{"given":"Tingting","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangyan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengming","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xixiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aoli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenliang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huamin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingwang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenquan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenchao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9513-3591","authenticated-orcid":false,"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixiang","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingsong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2021.173944_bib1","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.leukres.2010.04.016","article-title":"BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review","volume":"10","author":"An","year":"2010","journal-title":"Leuk. Res."},{"key":"10.1016\/j.ejphar.2021.173944_bib2","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(13)62120-0","article-title":"Chronic myeloid leukemia","volume":"385","author":"Apperley","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2021.173944_bib3","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"20","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2021.173944_bib4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.exphem.2018.04.007","article-title":"Experimental and integrative analyses identify an ETS1 network downstream of BCR-ABL in chronic myeloid leukemia (CML)","volume":"64","author":"Desterke","year":"2018","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.ejphar.2021.173944_bib5","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00262-018-2129-9","article-title":"The BCR-ABL inhibitor nilotinib influences phenotype and function of monocyte-derived human dendritic cells","volume":"5","author":"Dorfel","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ejphar.2021.173944_bib6","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.hoc.2011.09.005","article-title":"BCR-ABL mutations in chronic myeloid leukemia","volume":"5","author":"Ernst","year":"2011","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"10.1016\/j.ejphar.2021.173944_bib7","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2021.173944_bib8","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.mpmed.2017.02.004","article-title":"Chronic myeloid leukemia","volume":"5","author":"Hanlon","year":"2017","journal-title":"Medicine"},{"key":"10.1016\/j.ejphar.2021.173944_bib9","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0925-4439(02)00095-9","article-title":"Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1","volume":"1587","author":"Hegedus","year":"2002","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejphar.2021.173944_bib10","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/sj.leu.2403426","article-title":"Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance","volume":"8","author":"Hochhaus","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.ejphar.2021.173944_bib11","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/ajh.24275","article-title":"Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring","volume":"2","author":"Jabbour","year":"2016","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ejphar.2021.173944_bib12","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.clml.2015.03.006","article-title":"Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm","volume":"6","author":"Jabbour","year":"2015","journal-title":"Clin. Lymphoma, Myeloma & Leukemia"},{"key":"10.1016\/j.ejphar.2021.173944_bib13","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/376785a0","article-title":"Activation of the c-Abl tyrosine kinase in the stress response to DNA-damaging agents","volume":"376","author":"Kharbanda","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2021.173944_bib14","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/0092-8674(84)90438-0","article-title":"An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity","volume":"37","author":"Konopka","year":"1984","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2021.173944_bib15","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1084\/jem.189.9.1399","article-title":"The P190, BCR-ABL, and P230 forms of the BCR\/ABL oncogene induce a similar chronic myeloid leukemia\u2013like syndrome in mice but have different lymphoid leukemogenic activity","volume":"189","author":"Li","year":"1999","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejphar.2021.173944_bib16","doi-asserted-by":"crossref","first-page":"10033","DOI":"10.1021\/jm301188x","article-title":"Design, synthesis, and biological evaluation of 3-(1H-1,2,3-Triazol-1-yl)benzamide derivatives as potent Pan Bcr-Abl inhibitors including the Threonine315\u2192Isoleucine315 mutant","volume":"22","author":"Li","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2021.173944_bib17","doi-asserted-by":"crossref","first-page":"8456","DOI":"10.1021\/acs.jmedchem.6b00902","volume":"18","author":"Li","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2021.173944_bib18","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejmech.2018.10.007","volume":"160","author":"Liu","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejphar.2021.173944_bib19","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/jnci\/djx236","article-title":"Targeting BCR-ABL-independent TKI resistance in chronic myeloid leukemia by mTOR and autophagy inhibition","volume":"5","author":"Mitchell","year":"2018","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ejphar.2021.173944_bib20","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.critrevonc.2017.10.002","article-title":"Ponatinib in chronic myeloid leukemia (CML): consensus on patient treatment and management from a European expert panel","volume":"120","author":"Muller","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ejphar.2021.173944_bib21","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1021\/acs.jmedchem.6b01862","article-title":"Design and discovery of N-(2-Methyl-5\u2032-morpholino-6\u2032-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3\u2032-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): a potent, selective, and efficacious RAF inhibitor targeting RAS mutant cancers","volume":"60","author":"Nishiguchi","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2021.173944_bib22","doi-asserted-by":"crossref","first-page":"12643","DOI":"10.1007\/s13277-016-5179-7","article-title":"Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment","volume":"9","author":"Oaxaca","year":"2016","journal-title":"Tumour Biol."},{"key":"10.1016\/j.ejphar.2021.173944_bib23","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.leukres.2017.01.005","article-title":"Current approach to the treatment of chronic myeloid Leukemia","volume":"55","author":"Pasic","year":"2017","journal-title":"Leuk. Res."},{"key":"10.1016\/j.ejphar.2021.173944_bib24","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ccr.2014.08.010","article-title":"Structure, function, and resistance in chronic myeloid leukemia","volume":"3","author":"Radich","year":"2014","journal-title":"Canc. Cell"},{"key":"10.1016\/j.ejphar.2021.173944_bib25","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Canc. Cell"},{"key":"10.1016\/j.ejphar.2021.173944_bib26","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet","volume":"5","author":"Soverini","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2021.173944_bib27","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/cncr.31232","article-title":"Dasatinib dose management for the treatment of chronic myeloid leukemia","volume":"8","author":"Talpaz","year":"2018","journal-title":"Cancer"},{"issue":"Suppl. 1","key":"10.1016\/j.ejphar.2021.173944_bib28","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.leukres.2003.10.005","article-title":"Mechanisms of transformation by the BCR-ABL oncogene: new perspectives in the post-imatinib era","volume":"28","author":"Van Etten","year":"2004","journal-title":"Leuk. Res."},{"key":"10.1016\/j.ejphar.2021.173944_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2008.06.003","article-title":"Imatinib resistance in CML","volume":"1","author":"Volpe","year":"2009","journal-title":"Canc. Lett."},{"key":"10.1016\/j.ejphar.2021.173944_bib30","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ejphar.2017.06.001","article-title":"SHC004-221A1, a novel tyrosine kinase, potently inhibits T315I mutant BCR-ABL in chronic myeloid leukemia","volume":"811","author":"Wang","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2021.173944_bib31","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1021\/acs.jmedchem.6b01290","article-title":"Discovery of 4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((1-nicotinoylpiperidin-4-yl)oxy) benzamide (CHMFL-ABL\/KIT-155) as a novel highly potent type II ABL\/KIT dual kinase inhibitor with a distinct hinge binding","volume":"1","author":"Wang","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2021.173944_bib32","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1182\/blood-2007-08-109330","article-title":"Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells","volume":"7","author":"Wu","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2021.173944_bib33","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","article-title":"BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia","volume":"3","author":"Zabriskie","year":"2014","journal-title":"Canc. Cell"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299921000972?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299921000972?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T22:47:36Z","timestamp":1757976456000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299921000972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":33,"alternative-id":["S0014299921000972"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2021.173944","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML)","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2021.173944","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"173944"}}